论文部分内容阅读
目的评价疏血通与依达拉奉治疗进展性脑梗死的有效性和安全性。方法 60例进展性脑梗死患者随机分为治疗组和对照组,每组各30例。对照组用常规治疗方法舒血宁、复方丹参和营养脑细胞药物,治疗组用疏血通与依达拉奉和营养脑细胞药物。疗程均为14d。结果治疗组总有效率为86.7%,明显高于对照组70%,(P<0.05),治疗为14d,治疗组神经功能缺损程度评分明显改善,治疗组出现1例肾功能轻度异常,1例肝功能轻度异常均无给予处理,一周后正常,显示良好的安全性。结论疏血通加用依达拉奉治疗进展性脑梗死效果显著,有效安全值得临床推广。
Objective To evaluate the efficacy and safety of Shuxuetong and edaravone in the treatment of advanced cerebral infarction. Methods Sixty patients with progressive cerebral infarction were randomly divided into treatment group and control group, with 30 cases in each group. The control group with conventional treatment Shuxuening, Salvia miltiorrhiza compound and nutrition brain cell drugs, the treatment group with Shuxuetong and edaravone and nutrition brain cell drugs. Treatment are 14d. Results The total effective rate in the treatment group was 86.7%, significantly higher than that in the control group (P <0.05). The treatment group was 14 days. The score of neurological deficit in the treatment group was significantly improved. One case of mild renal dysfunction, 1 Cases of mild abnormal liver function were not given treatment, normal after a week, showing good safety. Conclusion Shuxuetong plus edaravone treatment of progressive cerebral infarction effect is significant, effective and safe clinical promotion.